Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Q4 2018 value amounting to $6.3 million.

  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue rose 1576.44% to $6.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.3 million, marking a year-over-year increase of 1576.44%. This contributed to the annual value of $6.3 million for FY2018, which is 1576.44% up from last year.
  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue amounted to $6.3 million in Q4 2018, which was up 1576.44% from $6.1 million recorded in Q3 2018.
  • Ironwood Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $10.5 million for Q4 2014, and its period low was $557000.0 during Q4 2016.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $6.2 million (2018), whereas its average is $6.3 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Non-Current Deffered Revenue crashed by 9129.01% in 2016 and then skyrocketed by 87827.65% in 2017.
  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $10.5 million in 2014, then plummeted by 39.22% to $6.4 million in 2015, then tumbled by 91.29% to $557000.0 in 2016, then surged by 878.28% to $5.4 million in 2017, then rose by 15.76% to $6.3 million in 2018.
  • Its Non-Current Deffered Revenue stands at $6.3 million for Q4 2018, versus $6.1 million for Q3 2018 and $6.1 million for Q2 2018.